Private company

Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc. is an American biological products company that raised $10 in 2022 (SEC Form D).2 It is headquartered in San Diego, United States.2

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersSan Diego, United States2
  • Incorporated inDE3
  • Business address2000 Central Avenue, Suite 100, Boulder, Co 803013
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300QODBI5C7YUJE092
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 21249792

See how the biggest companies compare on our leaderboards

On September 19, 2023, we announced the Plan of Dissolution and our intent to discontinue all clinical and preclinical development programs and reduce our workforce. Historically, we were a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics. Our pipeline aimed to disrupt existing treatment paradigms and featured several new chemical entities that inhibit novel targets with first-in-class potential for autoimmune, inflammatory, and other debilitating diseases.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-79.4%Operating margin6
-71.1%Net margin6
15.3%Revenue growth, 20236
-57.3%Return on equity6

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development40¢$3.2M
  • Other costs60¢$4.8M
  • Interest0¢$5.0K

Out of $8.0M in revenue.6 The company lost money this year.

Financial statements

Revenue78910116$8.0M in 2023−40% since 2017
0$5.0M$10.0M$15.0M2017: $13.4M$13.4M20172018: $10.9M$10.9M2018−19%2019: $7.9M$7.9M2019−27%2020: $1.8M$1.8M2020−77%2021: $404.0K$404.0K2021−78%2022: $6.9M$6.9M2022+1619%2023: $8.0M$8.0M2023+15%
Operating income78910116-$6.4M in 2023−52% since 2017
-$60.0M-$40.0M-$20.0M02017: -$13.4M-$13.4M20172018: -$8.5M-$8.5M2018−37%2019: -$24.5M-$24.5M2019+190%2020: -$21.0M-$21.0M2020−14%2021: -$40.2M-$40.2M2021+92%2022: -$21.5M-$21.5M2022−46%2023: -$6.4M-$6.4M2023−70%
Net income78910116-$5.7M in 2023−56% since 2017
-$40.0M-$30.0M-$20.0M-$10.0M02017: -$13.0M-$13.0M20172018: -$9.2M-$9.2M2018−29%2019: -$23.9M-$23.9M2019+159%2020: -$20.9M-$20.9M2020−12%2021: -$39.5M-$39.5M2021+89%2022: -$21.1M-$21.1M2022−47%2023: -$5.7M-$5.7M2023−73%
Fiscal year2017201820192020202120222023
Revenue$13.4M7$10.9M8$7.9M9$1.8M10$404.0K11$6.9M6$8.0M6
Research and development$14.4M7$13.0M8$20.2M9$11.2M10$28.2M11$14.0M6$3.2M6
Operating expenses$40.6M11$28.5M6$14.4M6
Operating income-$13.4M7-$8.5M8-$24.5M9-$21.0M10-$40.2M11-$21.5M6-$6.4M6
Interest$1.1M8$2.1M9$010$69.0K11$9.0K6$5.0K6
Income tax$07$07
Net income-$13.0M7-$9.2M8-$23.9M9-$20.9M10-$39.5M11-$21.1M6-$5.7M6
Earnings per share-$0.8510-$22.1211-$7.516-$1.066
Earnings per share (diluted)-$0.8510-$22.1211-$7.516-$1.066
Shares (weighted, basic)1.8M shares112.8M shares65.4M shares6
Shares (weighted, diluted)1.8M shares112.8M shares65.4M shares6

Compare Fresh Tracks Therapeutics, Inc. with another company

Corporate structure

Fresh Tracks Therapeutics, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Fresh Tracks Therapeutics, Inc.

  • Exploration Capital, LLC Filed SC 13D on Fresh Tracks Therapeutics, Inc., latest May 8, 2024 (2 filings since Jan 18, 2024)
  • Exploration Capital Fund, LP Filed SC 13G on Fresh Tracks Therapeutics, Inc., latest Nov 28, 2023
  • Ionic Ventures, LLC Filed SC 13G/A on Fresh Tracks Therapeutics, Inc., latest Feb 13, 2023 (3 filings since Nov 3, 2021)
  • Fresh Tracks Therapeutics, Inc. San Diego, California, United States
    • Brickell Subsidiary, Inc. Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Fresh Tracks Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$34.0K6 Dec 31, 2023$75.0K6 Dec 31, 2022−54.7%
Operating-lease assets (leased space)$06 Dec 31, 2023$49.0K6 Dec 31, 2022−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$10.9M6 Dec 31, 2023$8.7M6 Dec 31, 2022+25.2%

Leadership

Who has led Fresh Tracks Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Vijay B. Samant2006–2018
  2. George B. Abercrombie2020
  3. Andrew D. Sklawer2023
  4. Albert N. Marchio Ii.2024

Chair

  1. Reginald L. Hardy2019–2022

President

  1. Vijay B. Samant2006–2018
  2. Andrew D. Sklawer2023

Chief financial officer

  1. Jill Marie Church2006–2013
  2. Anthony Alan Ramos2017–2018
  3. Albert N. Marchio Ii.2020–2024

Chief operating officer

  1. Andrew D. Sklawer2019–2022
  2. Deepak Chadha2023
2010201520202025
Board members and other officers (25)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorRobert Busard Brown named Jun 7, 202248

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Brickell Subsidiary, Inc. Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Brickell Biotech, Inc.Sep 3, 2019 to Sep 6, 20223
  • VICAL INCFeb 15, 1995 to Aug 30, 20193
  • VICAL, INC.Feb 11, 1994 to Feb 11, 19943

Timeline

  1. Mar 7, 20248-K Ended a material agreement49
  2. Feb 16, 20248-K Shareholder vote50
  3. Jan 9, 2024New chief executive Albert N. Marchio Ii. becomes CEO14
  4. Jan 3, 20248-K Ended a material agreement; Executive or director change51
  5. Dec 27, 20238-K Shareholder vote; Regulation FD disclosure52
  6. Dec 18, 20238-K Listing notice or transfer; Regulation FD disclosure53
  7. Dec 15, 20238-K Shareholder vote; Regulation FD disclosure54
  8. Dec 15, 20238-K Entered a material agreement55
  9. Dec 1, 20238-K Shareholder vote; Regulation FD disclosure56
  10. Nov 17, 20238-K Shareholder vote; Regulation FD disclosure57
  11. Nov 13, 20238-K Results of operations58
  12. Oct 13, 20238-K Listing notice or transfer59
  13. Oct 10, 20238-K Executive or director change60
  14. Oct 4, 2023New chief executive Andrew D. Sklawer becomes CEO15
  15. Feb 19, 2020New chief executive George B. Abercrombie becomes CEO16
  16. Jan 3, 2006New chief executive Vijay B. Samant becomes CEO17
  17. Apr 30, 1987Founded Fresh Tracks Therapeutics, Inc. is founded2

Calendar

When it reported results

  1. Nov 13, 2023Reported quarterly or annual results58
  2. Aug 11, 2023Reported quarterly or annual results61
  3. May 10, 2023Reported quarterly or annual results62
  4. Mar 30, 2023Reported quarterly or annual results63
  5. Nov 10, 2022Reported quarterly or annual results64
  6. Aug 11, 2022Reported quarterly or annual results65
  7. May 12, 2022Reported quarterly or annual results66
  8. Mar 15, 2022Reported quarterly or annual results67

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

191 filings to the SEC since October 2021: 4 annual reports, 8 quarterly reports, 48 major events, 44 insider forms, 6 large holders, 1 private raises, 80 other. The latest 20:

  1. Jun 11, 20244 PRIMARY DOCUMENT EDGAR
  2. May 31, 20244 PRIMARY DOCUMENT EDGAR
  3. May 23, 20244 PRIMARY DOCUMENT EDGAR
  4. May 20, 20244 PRIMARY DOCUMENT EDGAR
  5. May 8, 20244 PRIMARY DOCUMENT EDGAR
  6. May 8, 2024SC 13D SCHEDULE 13D EDGAR
  7. May 3, 20244 PRIMARY DOCUMENT EDGAR
  8. Apr 23, 20244 PRIMARY DOCUMENT EDGAR
  9. Apr 11, 20244 PRIMARY DOCUMENT EDGAR
  10. Apr 5, 20244 PRIMARY DOCUMENT EDGAR
  11. Apr 1, 20244 PRIMARY DOCUMENT EDGAR
  12. Mar 21, 20244 PRIMARY DOCUMENT EDGAR
  13. Mar 18, 202415-12G EDGAR
  14. Mar 15, 202410-K EDGAR
  15. Mar 13, 20244 PRIMARY DOCUMENT EDGAR
  16. Mar 7, 20248-K EDGAR
  17. Feb 28, 20244 PRIMARY DOCUMENT EDGAR
  18. Feb 22, 20244 PRIMARY DOCUMENT EDGAR
  19. Feb 16, 20248-K EDGAR
  20. Feb 14, 2024DEFA14A EDGAR

The 191 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

47 open-market trades by officers, directors and large owners since October 2021: 45 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 10, 2024Exploration Capital, LLC10% ownerBuy86,185$0.94$81.0KForm 4
Jun 7, 2024Exploration Capital, LLC10% ownerBuy319,315$0.94$300.2KForm 4
May 31, 2024Exploration Capital, LLC10% ownerBuy516$0.89$459Form 4
May 30, 2024Exploration Capital, LLC10% ownerBuy9,838$0.92$9.1KForm 4
May 29, 2024Exploration Capital, LLC10% ownerBuy80$0.87$70Form 4
May 23, 2024Exploration Capital, LLC10% ownerBuy15,627$0.91$14.2KForm 4
May 22, 2024Exploration Capital, LLC10% ownerBuy383$0.89$341Form 4
May 21, 2024Exploration Capital, LLC10% ownerBuy6,879$0.91$6.3KForm 4
May 20, 2024Exploration Capital, LLC10% ownerBuy797$0.91$725Form 4
May 16, 2024Exploration Capital, LLC10% ownerBuy73,768$0.92$67.9KForm 4
May 6, 2024Exploration Capital, LLC10% ownerBuy320$0.89$285Form 4
May 3, 2024Exploration Capital, LLC10% ownerBuy324$0.91$295Form 4
May 2, 2024Exploration Capital, LLC10% ownerBuy2,222$0.91$2.0KForm 4
May 1, 2024Exploration Capital, LLC10% ownerBuy162,351$0.92$149.4KForm 4
Apr 23, 2024Exploration Capital, LLC10% ownerBuy343$0.91$312Form 4
Apr 22, 2024Exploration Capital, LLC10% ownerBuy16,908$0.90$15.2KForm 4
Apr 19, 2024Exploration Capital, LLC10% ownerBuy4,277$0.91$3.9KForm 4
Apr 10, 2024Exploration Capital, LLC10% ownerBuy1,000$0.88$880Form 4
Apr 9, 2024Exploration Capital, LLC10% ownerBuy2,188$0.88$1.9KForm 4
Apr 5, 2024Exploration Capital, LLC10% ownerBuy1,050$0.91$956Form 4

All 47 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 25, 2022Raised $10 in a private offering of equity Form D: 1 investor so far Form D

SEC filer profile

How Fresh Tracks Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARFresh Tracks Therapeutics, Inc.1
  • CIK0000819050
  • Employer ID (EIN)93-09485541
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2000 Central Avenue, Suite 100, Boulder, CO 803011
  • Phone(720) 505-47551
  • Shares outstanding5,973,306 as of Mar 15, 20246
  • Public float$4.1M as of Jun 30, 20236
  • On EDGAR sinceFeb 11, 19941
  • Filings1,275 in all: 4 (454), 8-K (223), SC 13G/A (89), 10-Q (83), DEFA14A (36), SC 13G (36), 3 (32), DEF 14A (29)1
    All 48 form types

    EFFECT (24), 10-K (23), CT ORDER (23), S-8 POS (22), S-8 (20), 424B5 (19), CORRESP (19), UPLOAD (19), S-3 (12), PRE 14A (11), POS AM (10), 4/A (9), S-3/A (9), S-1/A (8), 424B2 (7), 424B3 (7), 10-K405 (5), FWP (5), S-1 (5), 424B4 (4), 8-K/A (4), 10-K/A (3), SC 13D (3), SC 13D/A (3), 10-Q/A (2), AW (2), S-1MEF (2), 15-12G (1), 25-NSE (1), 3/A (1), D (1), DEFM14A (1), DEFR14A (1), DEL AM (1), POS EX (1), PREM14A (1), PRER14A (1), REGDEX (1), RW (1), S-3MEF (1)

  • Latest filingsAnnual report (10-K) Mar 15, 2024
    Quarterly report (10-Q) Nov 13, 2023
    Proxy statement (DEF 14A) Jan 17, 2024
    Latest 8-K (8-K) Mar 7, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70